World Immunotherapy Congress
Date: 31 October 2017 - 2 November 2017
Congress Center Basel
Email: [email protected]
Telephone: +44 (0)207 092 1257
DISCOVER. DEVELOP. BRING TO MARKET. For biotech, pharma and their partners
The World Immunotherapy Congress is a critical industry gathering that focuses on the discovery, development, commercialisation and marketing of immunotherapies.
Launched last year, the World Immunotherapy Congress successfully brought together some of the top researchers working in big pharma, academia and biotech to talk about some of the hottest trends and therapeutics for 2016.
2017 will be looking at pushing the limits on cutting edge research and trials for one of the hottest therapeutics around, including:
- “Strategies for Oncology” keynote panel: Executive representatives from big pharma are coming together to discuss strategies to tackle oncology, including a short presentation from each representative on the current 5-10-year strategical plan. Representatives from Roche, GSK, Eli Lilly and Company, MSD and Pfizer will participate.
- The day three keynote session will focus on academic success and world leading research. Four high level academics will each speak about their most recent, ground-breaking work presenting stories and data.
- A new stream, “Moving from Phase III and Beyond” will be focusing on the crucial steps after phase III trials, through regulatory approval, scale up and tech transfer, manufacture and commercialisation. This will give valuable insight on how to move your formats from bench to bedside.
KEY SPEAKERS INCLUDE:
> Roy Baynes, SVP & Head, Global Clinical Development, Chief Medical Officer, MSD
> Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Co
> Puja Sapra, Executive Director, Pfizer Worldwide Research and Development
> Michael DeRidder, Senior Director, Early pipeline commercial strategy, Oncology, Cell Therapy, GSK
> Sir Gregory Winter, Master of Trintity Cambridge Universiry, Founder and co-Founder, Bicycle Therapeutics
> Andre Choulika, CEO, Cellectis
> Hans G. Klingemann, Vice President, Research & Development, NantKwest
> John Delaney, Executive Director, Amgen Biologics Discovery
> Andreas Plückthun, Professor of Biochemistry, Director, Department of Biochemistry, University of ZurichAndreas Hougaard Laustsen, Postdoctoral Fellow, Tropical Pharmacology Lab, Technical University of Denmark
> Christian Rommel, Global Head of Oncology Discovery, Roche
> Zelig Eshhar, Professor of Chemical and Cellular Immunology, The Weizmann Institute